Promethazine is a medication used to manage and treat allergic conditions, nausea and vomiting, motion sickness, and sedation. Promethazine also has off-label uses for nausea and vomiting in pregnancy. Promethazine is a phenothiazine-class first-generation H1 receptor antagonist with marked antihistaminic, antiemetic, anticholinergic, and sedative properties; it is usually administered as promethazine hydrochloride in oral, rectal, syrup, and intramuscular or intravenous forms. After oral dosing promethazine shows variable bioavailability due to first-pass hepatic metabolism; Tmax is commonly reached within 1 to 3 hours and terminal half-life is typically in the range of 10 to 14 hours in adults. Hepatic metabolism produces N-demethylated and oxidized metabolites including promethazine sulfoxide; elimination is mainly renal as metabolites. Clinical use considerations include dose adjustment for elderly patients, avoidance in children under two years, potential for anticholinergic adverse effects, and interactions with central nervous system depressants and certain cytochrome P450 substrates or inhibitors.
Quality control of promethazine active substance and finished products monitors a defined set of related compounds and degradation products, most commonly promethazine sulfoxide (oxidation product), N-desmethyl-promethazine (demethylation), promethazine N-oxide, and trace phenothiazine-related impurities; other process-related residues can include synthesis intermediates and solvent traces. Typical manufacturing specifications used in regulatory and pharmacopeial practice set acceptance criteria for impurities such that any unspecified individual impurity is generally limited to about 0.2 to 0.5 percent by weight, specific identified impurities may be limited to 0.05 to 0.2 percent depending on their qualification status, and total impurities are commonly limited to about 1.0 to 2.0 percent, with tighter limits applied where safety or stability data require; these limits are confirmed and monitored by validated analytical methods such as HPLC with appropriate detection and mass spectral confirmation when needed.
Promethazine is used to relieve symptoms of allergic reactions such as rhinitis and urticaria, to prevent and treat nausea and vomiting including motion sickness, and to provide sedation or preoperative sedation; clinicians may also prescribe it off-label for hyperemesis gravidarum when appropriate and after risk assessment.
Promethazine is marketed under several brand names in India depending on the manufacturer; common brand names include Phenergan and generic promethazine hydrochloride formulations produced by multiple pharmaceutical companies, so the exact brand can vary by distributor and region.
Promethazine produces sedative effects that can be pronounced in many patients because of its central H1 antagonism and anticholinergic activity; it is used for short-term symptomatic relief of insomnia in some clinical settings, but it is not a first-line hypnotic and long-term use for sleep is not generally recommended due to tolerance, next-day drowsiness, and anticholinergic risks.
In mental health contexts promethazine is not a primary antipsychotic but may be used adjunctively for symptomatic management such as treating agitation, acute nausea from psychotropic medications, or as an antiemetic during psychiatric medication changes; it has limited antipsychotic activity and should be used under psychiatric supervision with attention to interactions and side effect profiles.
